Table 2.

Change in glycated hemoglobin (HbA1c) from baseline at week 26

	Placebo	E5/S100	E15/S100
Baseline	n = 96	n = 98	n = 96
Mean (SD), %	9.0 (0.9)	8.9 (0.9)	9.0 (0.9)
Mean (SD), mmol/mol	74.3 (9.4)	73.7 (9.5)	74.6 (9.5)
Week 26	n = 49	n = 85	n = 82
Mean (SD), %	8.0 (1.1)	7.2 (1.0)	7.3 (1.0)
Mean (SD), mmol/mol	64.0 (12.3)	54.8 (10.9)	56.0 (11.0)
Change from baseline at week 26	n = 96	n = 98	n = 96
Mean (SD), %	− 0.8 (1.1)	− 1.7 (0.9)	− 1.7 (1.1)
Mean (SD), mmol/mol	− 8.5 (11.6)	− 18.4 (9.8)	− 18.3 (11.7)
LS mean (95% CI), %	− 0.4 (− 0.7, − 0.2)	− 1.6 (− 1.8, − 1.4)	− 1.7 (− 1.9, − 1.5)
LS mean (95% CI), mmol/mol	− 4.8 (− 7.6, − 2.1)	− 17.5 (− 19.9, − 15.1)	− 18.4 (− 20.8, − 16.0)
Pairwise comparison vs. placebo
Difference in LS means (95% CI), %	–	− 1.2 (− 1.5, − 0.8)	− 1.2 (− 1.6, − 0.9)
Difference in LS means (95% CI), mmol/mol	–	− 12.7 (− 16.2, − 9.1)	− 13.5 (− 17.1, − 10.0)
P value	–	< 0.001	< 0.001

CI confidence interval, E ertugliflozin, LS least squares, S sitagliptin, SD standard deviation